CN102964271B - 沙坦类抗高血压药物中间体2-氰基-4’-甲基联苯的合成方法 - Google Patents
沙坦类抗高血压药物中间体2-氰基-4’-甲基联苯的合成方法 Download PDFInfo
- Publication number
- CN102964271B CN102964271B CN201210505580.0A CN201210505580A CN102964271B CN 102964271 B CN102964271 B CN 102964271B CN 201210505580 A CN201210505580 A CN 201210505580A CN 102964271 B CN102964271 B CN 102964271B
- Authority
- CN
- China
- Prior art keywords
- cyano
- catalyst
- tetrahydrofuran
- synthesizing
- chlorotoluene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000001308 synthesis method Methods 0.000 title abstract description 5
- 239000003814 drug Substances 0.000 title abstract description 4
- 230000003276 anti-hypertensive effect Effects 0.000 title abstract description 3
- 235000010290 biphenyl Nutrition 0.000 title abstract 3
- 239000004305 biphenyl Substances 0.000 title abstract 3
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 title abstract 3
- NPDACUSDTOMAMK-UHFFFAOYSA-N 4-Chlorotoluene Chemical compound CC1=CC=C(Cl)C=C1 NPDACUSDTOMAMK-UHFFFAOYSA-N 0.000 claims abstract description 31
- NHWQMJMIYICNBP-UHFFFAOYSA-N 2-chlorobenzonitrile Chemical compound ClC1=CC=CC=C1C#N NHWQMJMIYICNBP-UHFFFAOYSA-N 0.000 claims abstract description 25
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 72
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 45
- 239000003054 catalyst Substances 0.000 claims description 43
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 36
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 33
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 26
- ZGQVZLSNEBEHFN-UHFFFAOYSA-N 2-(4-methylphenyl)benzonitrile Chemical group C1=CC(C)=CC=C1C1=CC=CC=C1C#N ZGQVZLSNEBEHFN-UHFFFAOYSA-N 0.000 claims description 25
- 238000000034 method Methods 0.000 claims description 18
- 239000002904 solvent Substances 0.000 claims description 18
- 238000003756 stirring Methods 0.000 claims description 16
- 239000003960 organic solvent Substances 0.000 claims description 15
- 239000012044 organic layer Substances 0.000 claims description 13
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 12
- 238000001953 recrystallisation Methods 0.000 claims description 11
- 230000002194 synthesizing effect Effects 0.000 claims description 11
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 7
- 239000000460 chlorine Substances 0.000 claims description 6
- 239000013078 crystal Substances 0.000 claims description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 5
- 238000001816 cooling Methods 0.000 claims description 5
- 238000001035 drying Methods 0.000 claims description 5
- 238000010438 heat treatment Methods 0.000 claims description 5
- 239000010410 layer Substances 0.000 claims description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 5
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 4
- 229910052801 chlorine Inorganic materials 0.000 claims description 4
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims description 3
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical group C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 claims description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 2
- 238000005406 washing Methods 0.000 claims description 2
- 238000006243 chemical reaction Methods 0.000 abstract description 24
- 239000002994 raw material Substances 0.000 abstract description 5
- 230000003197 catalytic effect Effects 0.000 abstract 1
- 239000000047 product Substances 0.000 description 16
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- 239000000543 intermediate Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 239000002220 antihypertensive agent Substances 0.000 description 4
- 229940127088 antihypertensive drug Drugs 0.000 description 4
- 239000000376 reactant Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 239000007832 Na2SO4 Substances 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 239000003208 petroleum Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 229910052938 sodium sulfate Inorganic materials 0.000 description 3
- ZBTMRBYMKUEVEU-UHFFFAOYSA-N 1-bromo-4-methylbenzene Chemical compound CC1=CC=C(Br)C=C1 ZBTMRBYMKUEVEU-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 239000007818 Grignard reagent Substances 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 150000001805 chlorine compounds Chemical class 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 150000004795 grignard reagents Chemical class 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- 238000009776 industrial production Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000012046 mixed solvent Substances 0.000 description 2
- 230000036632 reaction speed Effects 0.000 description 2
- SMQUZDBALVYZAC-UHFFFAOYSA-N salicylaldehyde Chemical compound OC1=CC=CC=C1C=O SMQUZDBALVYZAC-UHFFFAOYSA-N 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- 125000006732 (C1-C15) alkyl group Chemical group 0.000 description 1
- OZMLUMPWPFZWTP-UHFFFAOYSA-N 2-(tributyl-$l^{5}-phosphanylidene)acetonitrile Chemical compound CCCCP(CCCC)(CCCC)=CC#N OZMLUMPWPFZWTP-UHFFFAOYSA-N 0.000 description 1
- AFMPMSCZPVNPEM-UHFFFAOYSA-N 2-bromobenzonitrile Chemical compound BrC1=CC=CC=C1C#N AFMPMSCZPVNPEM-UHFFFAOYSA-N 0.000 description 1
- DFRAKBCRUYUFNT-UHFFFAOYSA-N 3,8-dicyclohexyl-2,4,7,9-tetrahydro-[1,3]oxazino[5,6-h][1,3]benzoxazine Chemical compound C1CCCCC1N1CC(C=CC2=C3OCN(C2)C2CCCCC2)=C3OC1 DFRAKBCRUYUFNT-UHFFFAOYSA-N 0.000 description 1
- 241000772991 Aira Species 0.000 description 1
- 239000002083 C09CA01 - Losartan Substances 0.000 description 1
- 239000002080 C09CA02 - Eprosartan Substances 0.000 description 1
- 239000004072 C09CA03 - Valsartan Substances 0.000 description 1
- 239000002947 C09CA04 - Irbesartan Substances 0.000 description 1
- 0 Cc(c(C(c1ccccc1)c1ccccc1)c1)c(C(*)c2ccccc2)cc1Cl Chemical compound Cc(c(C(c1ccccc1)c1ccccc1)c1)c(C(*)c2ccccc2)cc1Cl 0.000 description 1
- 241000708493 Gelina Species 0.000 description 1
- 229910021380 Manganese Chloride Inorganic materials 0.000 description 1
- GLFNIEUTAYBVOC-UHFFFAOYSA-L Manganese chloride Chemical compound Cl[Mn]Cl GLFNIEUTAYBVOC-UHFFFAOYSA-L 0.000 description 1
- NFHFRUOZVGFOOS-UHFFFAOYSA-N Pd(PPh3)4 Substances [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 1
- 101100226004 Rattus norvegicus Erc2 gene Proteins 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229960004563 eprosartan Drugs 0.000 description 1
- OROAFUQRIXKEMV-LDADJPATSA-N eprosartan Chemical compound C=1C=C(C(O)=O)C=CC=1CN1C(CCCC)=NC=C1\C=C(C(O)=O)/CC1=CC=CS1 OROAFUQRIXKEMV-LDADJPATSA-N 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 229960002198 irbesartan Drugs 0.000 description 1
- YCPOHTHPUREGFM-UHFFFAOYSA-N irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2[N]N=NN=2)C(CCCC)=NC21CCCC2 YCPOHTHPUREGFM-UHFFFAOYSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- UBJFKNSINUCEAL-UHFFFAOYSA-N lithium;2-methylpropane Chemical compound [Li+].C[C-](C)C UBJFKNSINUCEAL-UHFFFAOYSA-N 0.000 description 1
- 229960004773 losartan Drugs 0.000 description 1
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000011565 manganese chloride Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 229960004699 valsartan Drugs 0.000 description 1
- SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
Images
Landscapes
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Abstract
Description
有机溶剂 | 转化率 | 选择率 | 产品纯度 |
吡啶 | 84 | 69 | 86.8 |
N-甲基吡咯烷酮 | 72 | 64 | 87.6 |
甲苯 | 82 | 88 | 99.0 |
四氢呋喃 | 84 | 66 | 94.8 |
吡啶、四氢呋喃混合物(1:1体积比混合) | 92 | 88 | 99.4 |
苯 | 70 | 67 | 84.4 |
石油醚 | 32 | 28 | 80.6 |
N,N-二甲基甲酰胺 | 63 | 73 | 81.4 |
Claims (9)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210505580.0A CN102964271B (zh) | 2012-12-03 | 2012-12-03 | 沙坦类抗高血压药物中间体2-氰基-4’-甲基联苯的合成方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210505580.0A CN102964271B (zh) | 2012-12-03 | 2012-12-03 | 沙坦类抗高血压药物中间体2-氰基-4’-甲基联苯的合成方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102964271A CN102964271A (zh) | 2013-03-13 |
CN102964271B true CN102964271B (zh) | 2014-05-14 |
Family
ID=47794739
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201210505580.0A Expired - Fee Related CN102964271B (zh) | 2012-12-03 | 2012-12-03 | 沙坦类抗高血压药物中间体2-氰基-4’-甲基联苯的合成方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102964271B (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108623497B (zh) * | 2018-07-13 | 2021-07-30 | 上海启讯医药科技有限公司 | 一种2-氰基-4’-甲基联苯的制备方法 |
CN114539096A (zh) * | 2022-03-25 | 2022-05-27 | 济南大学 | 一种4-甲基-2-氰基联苯制备方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5288895A (en) * | 1992-04-13 | 1994-02-22 | Elf Sanofi | Process for the preparation of a biphenyl derivative |
CN101531617A (zh) * | 2008-03-14 | 2009-09-16 | 施凯翔 | 降血压药aⅱra中间体2-腈基4’-甲基联苯的制备方法 |
CN102659622A (zh) * | 2012-05-14 | 2012-09-12 | 山东轻工业学院 | 一种大位阻配体Pd配合物催化剂及其制备方法及应用 |
-
2012
- 2012-12-03 CN CN201210505580.0A patent/CN102964271B/zh not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5288895A (en) * | 1992-04-13 | 1994-02-22 | Elf Sanofi | Process for the preparation of a biphenyl derivative |
CN101531617A (zh) * | 2008-03-14 | 2009-09-16 | 施凯翔 | 降血压药aⅱra中间体2-腈基4’-甲基联苯的制备方法 |
CN102659622A (zh) * | 2012-05-14 | 2012-09-12 | 山东轻工业学院 | 一种大位阻配体Pd配合物催化剂及其制备方法及应用 |
Non-Patent Citations (4)
Title |
---|
2-氰基-4’-甲基联苯的合成;魏开红;《化学与生物工程》;20041231;第21卷(第3期);第39页 * |
沙坦联苯的合成工艺研究;鲁金樑;《江西科学》;20090430;第27卷(第2期);第260页 * |
魏开红.2-氰基-4’-甲基联苯的合成.《化学与生物工程》.2004,第21卷(第3期),39-41. |
鲁金樑.沙坦联苯的合成工艺研究.《江西科学》.2009,第27卷(第2期),259-262. |
Also Published As
Publication number | Publication date |
---|---|
CN102964271A (zh) | 2013-03-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102924424B (zh) | 一种合成盐酸多塞平的方法 | |
CN107936029B (zh) | 一种合成瑞博西尼的方法 | |
CN102030770A (zh) | 一种芳香硼酸酯化合物的制备方法 | |
CN103012201B (zh) | 2-氰基-4’-甲基联苯的合成方法 | |
CN101597243B (zh) | 一种2-氰基-4’-溴甲基联苯的合成方法 | |
CN102964271B (zh) | 沙坦类抗高血压药物中间体2-氰基-4’-甲基联苯的合成方法 | |
CN102617586B (zh) | 地瑞那韦中间体的制备方法 | |
CN104926785B (zh) | 一种硒杂芳环衍生物及其制备方法 | |
CN102701936A (zh) | 芴氧化生产9-芴酮的方法 | |
CN102942503B (zh) | 沙坦类抗高血压药物中间体2-氰基-4’-甲基联苯的制备方法 | |
CN106588745B (zh) | 一种苯并烯氟菌唑的中间体及其制备方法和应用 | |
CN111039860B (zh) | 2-羟基-n-(4’-氯联苯-2-基)烟酰胺的合成方法及应用 | |
CN102391175B (zh) | 2,2'-联吡啶-4,4'-二甲醛的绿色合成方法 | |
CN104628630A (zh) | 一种茚衍生物1-吡啶基-2-溴茚及其合成方法 | |
CN111362795B (zh) | 一类取代丁酸酯类衍生物的制备方法 | |
CN104086456A (zh) | 一种沙坦联苯的合成方法 | |
CN103992261A (zh) | 2-溴咔唑工业化制备工艺 | |
CN109232381B (zh) | 9-([1,1′-联苯]-3-基)-2′-溴-2,9′-联咔唑及其合成方法 | |
CN106905133B (zh) | 一种螺环芴并茚二酮类化合物及其制备方法和应用 | |
CN105254571B (zh) | 噌啉类化合物及其合成方法 | |
CN102190569A (zh) | 一种普拉格雷中间体α-环丙基羰基-2-氟苄基溴的制备方法 | |
CN110015960A (zh) | 1,3-二(4,4-甲酸甲酯苯基)丙酮的制备方法及应用 | |
CN103664700B (zh) | 一种1-乙基-3-(3-二甲基氨基丙基)-碳化二亚胺甲碘盐的合成方法 | |
CN110343127A (zh) | 一种9-硅芴衍生物的制备方法 | |
CN102718694A (zh) | 3-氰基取代吲哚化合物及其合成方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB02 | Change of applicant information | ||
CB02 | Change of applicant information |
Address after: 250353 Shandong Light Industries College, 3501 West University Town Science Park, Shandong, Ji'nan Applicant after: Qilu University of Technology Address before: 250353 Shandong Light Industries College, 3501 West University Town Science Park, Shandong, Ji'nan Applicant before: Shandong Institute of Light Industry |
|
COR | Change of bibliographic data |
Free format text: CORRECT: APPLICANT; FROM: SHANDONG INSTITUTE OF LIGHT INDUSTRY TO: QILU UNIVERSITY OF TECHNOLOGY |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20140514 Termination date: 20141203 |
|
EXPY | Termination of patent right or utility model |